ADVISORY, July 11, 2013 (GLOBE NEWSWIRE) --
MiMedx Group, Inc. [MDXG], an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane, will visit the NASDAQ MarketSite in Times Square.In honor of the occasion, Mr. Parker H. "Pete" Petit, Chairman & CEO will ring the Opening Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Friday, July 12, 2013 – 9:15 a.m. to 9:30 a.m. ET Contact: Michael Senken (770) 651-9105 email@example.com NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at: http://www.facebook.com/NASDAQ . For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx . Webcast: A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx . Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice. About MiMedx Group, Inc. [MDXG]: MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 160,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.